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Rearrangements of TCF3 (E2A) occur in o5% of childhood B-cell
precursor acute lymphoblastic leukemia (BCP-ALL) cases.1 In
90–95% of these rearranged cases, TCF3 (chromosome 19p13) is
fused to PBX1 (chromosome 1q23).2 This TCF3-rearranged subtype
is characterized by the expression of cytoplasmic immunoglobulin
heavy chain (CyIgm) in more than 80% of pediatric patients.3,4
This CyIgm positivity is a consequence of an in-frame VDJ
rearrangement of the immunoglobulin heavy chain locus (IGH).3
Igm and the surrogate light chain together constitute the pre-B-cell
receptor (pre-BCR).5 Activation of this pre-BCR triggers the clonal
expansion of pre-B cells in the bone marrow, after which these
cells further maturate by initiating the rearrangement of the light
chain locus genes IGK and IGL.6 The transcription factor TCF3 is
essential in the differentiation process of common lymphoid
progenitors into B-lineage cells and is a key regulator of further
B-cell development. TCF3-deficient cells are impaired in
rearranging both the immunoglobulin heavy and light chain
genes, and wild-type TCF3 regulates the expression of genes
important in B-cell differentiation such as EBF1 and PAX5.7,8 These
findings imply that TCF3-rearranged cases might be affected in
pre-BCR-mediated signaling, which in turn could point to new
therapeutic targets for this subtype of BCP-ALL. To address this
hypothesis, we investigated components of the pre-BCR pathway
in leukemic cells obtained from newly diagnosed children with
TCF3-rearranged BCP-ALL and non-TCF3-rearranged BCP-ALL.
In a representative childhood BCP-ALL cohort, 11/13 (84.6%) of
TCF3-rearranged cases were positive for CyIgm compared with 68/
325 (20.9%) of non-TCF3-rearranged cases (Po0.001; Figure 1a),
thereby confirming previous studies.3,4 We used a previously
validated PCR heteroduplex analysis9 of V(D)J rearrangement
patterns of the IGH, IGK and IGL genes to determine a difference in
the heavy and light chain rearrangement patterns of TCF3
and non-TCF3-rearranged cases. Four stages at which the
rearrangement had been arrested were defined: samples with
only rearrangements of IGH (IGH), samples with Vk-Jk
rearrangements but no IGK-Kde or Vl-Jl rearrangements IGK),
samples with IGK-Kde and no Vl-Jl rearrangements IGK-Kde),
and samples with Vl-Jl rearrangements (IGL). Strikingly, the
immunoglobulin rearrangement pattern of TCF3-rearranged cases
was arrested at the IGH stage in 86.4% (19/22) of the cases. Only
one case was assigned to the IGK group and two cases to the
IGL group. In contrast, only 17.9% (34/190) of the non-TCF3-
rearranged cases was arrested at the IGH stage and the frequency
of cases with light chain rearrangements was significantly
increased to 18.4% (35/190) for samples arrested at IGK, 38.4%
(73/190) for IGK-Kde and 24.7% (47/190) for IGL (Po0.001). In
one sample, that was representing a BCR-ABL1-like patient,
rearrangements of the heavy chain (IGH) and light chain genes
(IGK, IGL) did not occur (Figure 1b). These data demonstrate that
the majority of TCF3-rearranged BCP-ALL cases express the
immunoglobulin heavy chain without further initiating the
rearrangement and expression of the light chain needed to
mature further and form a functional B-cell receptor. This suggests
a divergent role for the pre-BCR and its downstream signaling in
TCF3-rearranged BCP-ALL.
Next, we analyzed the expression levels of several key
components of the pre-BCR signaling complex: ZAP70, SYK, LYN,
SLP65 (BLNK), BTK, PLCg2, PI3K-p110d, and IRF4 by reverse phase
protein arrays10 of leukemic cell lysates (containing 490%
leukemic blasts) obtained from 19 TCF3-rearranged and 113
non-TCF3 BCP-ALL pediatric patients. As visualized in Figure 1c,
most of these proteins were expressed significantly more in TCF3-
rearranged compared with non-TCF3-rearranged BCP-ALL: ZAP70
1.3-fold (Po0.001), SLP65 3.4-fold (P¼ 0.002), BTK 1.5-fold
(Po0.001), PI3K-p110d 1.2-fold (P¼ 0.02) and IRF4 5.2-fold
(Po0.001). In addition, the expression of the TCF3-target gene
EBF1 was 2.7-fold increased in TCF3-rearranged BCP-ALL cases
(Po0.001; Figure 1c).
The activity of this divergent pre-BCR pathway was evaluated
by responsiveness to the BTK inhibitor Ibrutinib (PCI-32765,
Selleckchem, Houston, TX, USA). Ibrutinib was demonstrated to
be of clinical benefit to patients suffering from chronic
lymphoblastic leukemia,11,12 B-cell non-Hodgkin lymphomas11
and multiple myeloma.13 We tested in primary BCP-ALL samples
and leukemic cell lines in a 72-h in vitro drug cytotoxicity
assay using methyl-thiazol-tetrazolium conversion as read-out.14
In correspondence with preclinical studies showing effective anti-
leukemic effect of Ibrutinib in primary chronic lymphoblastic
leukemia cells,15 a concentration range between 0 and 50 mM
Ibrutinib was used. In our study the growth and viability of the
TCF3-rearanged cell line MHH-CALL3 decreased upon exposure to
increasing concentrations of Ibrutinib (Figure 2a), resulting in a
growth inhibitory concentration (GI50) of 43.5 mM. In contrast, no
GI50 value was reached for non-TCF3-rearranged cell lines (Nalm6
and MHH-CALL4) nor the TCF3-rearranged cell line 697 (Figure 2a).
This latter cell line is known for its lack of functional BTK,16,17
suggesting relative specificity of Ibrutinib for BTK-mediated
pre-BCR signaling in BCP-ALL. In correspondence, the level of
phosphorylated ERK1/2, which is an important downstream
effector of BTK contributing to cell survival, decreased upon a
4-h exposure to Ibrutinib in the TCF3-rearranged MHH-CALL3 but
not in both non-TCF3-rearranged cell lines Nalm6 and MHH-CALL4
(as shown on western blot, Figure 2c). Figure 2b shows the
differential cytotoxic effect of Ibrutinib in primary patients’
leukemic cells of six TCF3-rearranged and six non-TCF3-rearranged
BCP-ALL patients (490% leukemic blasts) taken at the initial
diagnosis (measured by methyl-thiazol-tetrazolium assay).
All TCF3-rearranged samples expressed CyIgm in contrast to 50%
(3/6) non-TCF3 samples, which represented two hyperdiploid
(450 chromosomes), two ETV6-RUNX1-translocated, one BCR-
ABL1-like and one BCR-ABL1-positive case. Ibrutinib significantly
reduced the cell viability of all TCF3-rearranged cases at each
inhibitor concentration compared with non-TCF3-rearranged cases
(Po0.001). As leukemic cells of patients do not proliferate in
ex vivo culture conditions, the concentration of Ibrutinib, which is
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Figure 1. Cytoplasmic Igm expression in TCF3 non-TCF3-rearranged B-cell precursor ALL (a). Patients were considered CyIgm positive if 430%
of leukemic cells were stained positively for this marker as detected by flow cytometry. Distribution of immunoglobulin rearrangement
pattern of TCF3-rearranged and non-TCF3-rearranged BCP-ALL cases (b). IGH group contains samples with IGH rearrangement only. IGK group
consists of cases with Vk-Jk rearrangements without IGK-Kde or Vl-Jl; IGK-Kde group contains IGK-deleted cases without Vl-Jl
rearrangements. IGL group contains cases with Vl-Jl-rearranged IGL locus. V(D)J rearrangement patterns were detected by genomic PCR
heteroduplex analysis as previously decribed.9 Expression level of proteins involved in pre-BCR signaling in TCF3-rearranged and non-TCF3-
rearranged BCP-ALL samples (c). Expression levels of indicated proteins were determined by reverse phase protein arrays using leukemic cell
lysates of newly diagnosed BCP-ALL patients. The protein level was detected in six spots per patient by specific antibodies and was
normalized for total protein loaded on each array. Red line indicates the median expression level per group. ***Po0.001, **Po0.01, *Po0.05
(a and b: w2-test; c: Mann–Whitney U-test). See Supplementary Materials and methods document for more information.
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Figure 2. Sensitivity of leukemic cells to the BTK inhibitor Ibrutinib. (a) Leukemic cell lines. (b) Patients’ leukemic cells. Experiments were
performed in duplicate. Dashed line indicates the Ibrutinib concentration affecting growth (GI50, cell lines) or inducing cell death (LC50,
patients’cells) in 50% of the cells. Bars indicate 95% confidence interval. P-value was calculated by one-way analysis of variance test with
repeated measurements. Effect of Ibrutinib on ERK protein levels in leukemic cell lines (c). Cell lines were exposed to 0, 50 and 150 mM Ibrutinib
for 4 h. The level of phosphorylated ERK1/2 (p-ERK1/2) was reduced in TCF3-rearranged MHH-CALL3 compared with non-TCF3-rearranged
Nalm6 and MHH-CALL4 cell lines. b-Actin served as a loading control. P-ERK/b-actin: ratio of the intensities. See Supplementary Materials and
methods document for more information.
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lethal to 50% (LC50) of the primary leukemic cells, was calculated.
The median LC50 value was 16.7mM for TCF3-rearranged cases,
whereas virtually no cell death was induced up to 50.0 mM of
Ibrutinib in leukemic samples of non-TCF3-rearranged patients
(Po0.001; Figure 2b). Strikingly, in our study the leukemic cell
samples of patients were more sensitive to cell death induced by
Ibrutinib than the growth inhibitory concentration needed for cell
lines. This suggests that TCF3-rearranged patients’ leukemic cells
have an activated pre-BCR signaling pathway. The observed LC50
values for TCF3-rearranged cells are comparable to previously
reported drug cytotoxicity data in primary chronic lymphoblastic
leukemia cells.15 In addition, Ibrutinib was shown to impair the
migration and adhesion of mature B cells to mesenchymal stromal
cells at sub-micromolar levels.18,19 Taken together, these studies
suggest that Ibrutinib is highly effective to target leukemic cells by
interfering with (pre)BCR-driven survival/proliferation signaling
and with migration/adhesion pathways.
Remarkably, we observed that TCF3-rearranged BCP-ALL cases
intrinsically express higher protein levels of pre-BCR pathway
including IRF4 (Figure 1c). In normal B-cell development, IRF4
triggers the rearrangement of the immunoglobulin light chain
genes IGK and IGL, thereby contributing to the maturation of the
B-cell receptor,20 whereas the present study shows that these light
chain genes are infrequently rearranged in TCF3-rearranged BCP-
ALL. Inhibition of TCF3 is essential for the successful production of
high-affinity immunoglobulins, a process that is mediated via a
negative-feedback loop of the mature B-cell receptor.21 Given the
presently available data, we would like to postulate that the
differentiation of TCF3-rearranged BCP-ALL is arrested at an early
stage in B-cell development, most likely resembling the
compartment of pre-B-II-large cells in normal hematopoiesis
before IRF4 triggers the rearrangements of immunoglobulin
light chains.20 The aberrantly high levels of IRF4 together with
activated pre-BCR signaling may trigger an uncontrolled
expansion of TCF3-rearranged cells in vivo at the expense of
differentiation into more mature B cells. In correspondence, the
relative sensitivity of TCF3-rearranged leukemic cells for
Ibrutinib—without need for external stimuli other than those
provided by the culture medium—and the aberrant expression
profile of pre-BCR-related proteins suggests that the pre-BCR
pathway is more activated in TCF3-rearranged compared with
non-TCF3-rearranged leukemic cells.
The prognosis of children with TCF3-rearranged leukemia has
improved during consecutive trials by optimizing the regimens
with traditional chemotherapeutic drugs.22 Implementation of
more specific, that is, targeted, drugs may further improve
prognosis and/or reduce the side effects of current
chemotherapeutics by allowing a dosage reduction. Early clinical
trials show that objective response rates can be obtained with
Ibrutinib in 60–75% of patients with relapsed or refractory B-cell
malignancies.11,23 A phase II study in adult patients with chronic
lymphoid leukemia indicates that monotherapy with Ibrutinib
might be effective even in high-risk cases with limited adverse
effects.23 These early clinical trial observations together with the
findings presented in this preclinical study provide a strong
rationale to design studies with agents interfering with pre-BCR
signaling (for example, Ibrutinib) in children with TCF3-rearranged
BCP-ALL.
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